TrialAdvances in therapy2026
Matching-Adjusted Indirect Comparison of Tarlatamab for Patients with Platinum-Refractory or Platinum-Resistant Extensive-Stage Small-Cell Lung Cancer.
Franziska Dirnberger et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.